WORTZMAN MITCHELL S 4
4 · MEDICIS PHARMACEUTICAL CORP · Filed Dec 13, 2012
Insider Transaction Report
Form 4
Transactions
- Disposition to Issuer
Common Stock
2012-12-11$44.00/sh−203,990$8,975,560→ 0 total - Disposition to Issuer
Common Stock
2012-12-11$44.00/sh−718$31,592→ 0 total(indirect: By 401(k))
Footnotes (2)
- [F1]On December 11, 2012, the Issuer completed its merger (the "Merger") with Valeant Pharmaceuticals International ("Valeant"), whereby the Issuer became a wholly owned subsidiary of Valeant, pursuant to an Agreement and Plan of Merger that was entered into on September 2, 2012 (the "Merger Agreement"). In accordance with the Merger Agreement, each share of common stock of the Issuer issued and outstanding immediately prior to the consummation of the Merger converted into a right to receive an amount in cash equal to $44.00 per share (the "Per Share Merger Consideration"), without interest. The amount of shares in Column 4 includes 170,866 restricted shares of common stock that also converted into a right to receive the Per Share Merger Consideration.
- [F2]Common stock of the Issuer held within the reporting person's 401(k) plan immediately prior to the consummation of the Merger converted into a right to receive the Per Share Merger Consideration.